Interleukin-6 in the pathogenesis of posterior capsule opacification and the potential role for interleukin-6 inhibition in the future of cataract surgery

Medical Hypotheses

Volumn 80, Issue 4, 2013, Pages 466-474

  Lewis, Aaron C ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GELATINASE A; GELATINASE B; INTERLEUKIN 6; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NONSTEROID ANTIINFLAMMATORY AGENT; SMALL INTERFERING RNA; STEROID; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CATARACT; CATARACT EXTRACTION; EYE DISEASE; EYE SURGERY; GENE SILENCING; HUMAN; LASER SURGERY; MOLECULAR PATHOLOGY; MONOTHERAPY; NEODYMIUM YAG LASER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STEROID THERAPY; SURGICAL TECHNIQUE; TH17 CELL; UVEITIS;

ANIMALS; CAPSULE OPACIFICATION; CATARACT EXTRACTION; CYTOKINES; HUMANS; INTERLEUKIN-6; MODELS, IMMUNOLOGICAL; PREMEDICATION;

EID: 84875389635     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.12.042     Document Type: Article

References (116)

1. Pandey S.K., Apple D.J., Werner L., Maloof A.J., Milverton E.J. Posterior capsule opacification: a review of the aetiopathogenesis, experimental and clinical studies and factors for prevention. Indian J Ophthalmol 2004, 52:99-112.
2. Apple D.J., Escobar-Gomez M., Zaugg B., Kleinmann G., Borkenstein A.F. Modern cataract surgery: unfinished business and unanswered questions. Surv Ophthalmol 2011, 56(Suppl. 6). S3-53.
3. Wormstone I.M., Liu C.S., Rakic J.M., Marcantonio J.M., Vrensen G.F., Duncan G. Human lens epithelial cell proliferation in a protein-free medium. Invest Ophthalmol Vis Sci 1997, 38:396-404.
4. Schaumberg D.A., Dana M.R., Christen W.G., Glynn R.J. A systematic overview of the incidence of posterior capsule opacification. Ophthalmology 1998, 105:1213-1221.
5. Dewey S. Posterior capsule opacification. Curr Opin Ophthalmol 2006, 17:45-53.
6. Wilson M.E., Trivedi R.H. The ongoing battle against posterior capsular opacification. Arch Ophthalmol 2007, 125:555-556.
7. Wormstone I.M., Tamiya S., Anderson I., Duncan G. TGFβ2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci 2002, 43(7):2301-2308.
8. Eballé A.O., Ellong A., Ella G.P., Dohvoma V.A., Bella A.L., Mvogo C.E. Secondary cataract: an epidemiologic and clinical survey at the Yaounde Gynaeco-obstetric and Paediatric Hospital. Clin Ophthalmol 2011, 5:847-851.
9. Hales A.M., Schulz M.W., Chamberlain C.G., McAvoy J.W. TGFβ1 induces lens cells to accumulate alpha-smooth muscle actin, a marker for subcapsular cataracts. Curr Eye Res 1994, 13:885-890.
10. de Iongh R.U., Wederell E., Lovicu F.J., McAvoy J.W. Transforming growth factor-beta-induced epithelial-mesenchymal transition in the lens: a model for cataract formation. Cells Tissues Organs 2005, 179:43-55.
11. McDonnel P.J., Zarbin M.A., Green W.R. Posterior capsule opacification in pseudophakic eyes. Ophthalmology 1983, 90:1548-1553.
12. Apple D.J., Peng Q., Visessook N., Werner L., Pandey S.K., Escobar-Gomez M., et al. Eradication of posterior capsule opacification: documentation of a marked decrease in Nd:YAG laser posterior capsulotomy rates noted in an analysis of 5416 pseudophakic human eyes obtained postmortem. Ophthalmology 2001, 108(3):505-518.
13. Peng Q., Visessook N., Apple D.J., et al. Surgical prevention of posterior capsule opacification. Part 3: intraocular lens optic barrier effect as a second line of defense. J Cataract Refract Surg 2000, 26:198-213.
14. Peng Q., Apple D.J., Visessook N., et al. Surgical prevention of posterior capsule opacification. Part 2: enhancement of cortical cleanup by focusing on hydrodissection. J Cataract Refract Surg 2000, 26:188-197.
15. Apple D.J., Peng Q., Visessook N., et al. Surgical prevention of posterior capsule opacification. Part I. how are we progressing in eliminating this complication of cataract surgery?. J Cataract Refract Surg. 2000, 26:180-187.
16. Newland T.J., McDermott M.L., Eliott D. Experimental neodymium:YAG laser damage to acrylic, poly(methyl methacrylate), and silicone intraocular lens materials. J Cataract Refract Surg 1999, 25:72-76.
17. Trinavarat A., Atchaneeyasakul L., Udompunturak S. Neodymium:YAG laser damage threshold of foldable intraocular lenses. J Cataract Refract Surg 2001, 27:775-780.
18. Ranta P., Tommila P., Immonen I. Retinal breaks before and after neodymium:YAG posterior capsulotomy. J Cataract Refract Surg 2000, 26:1190-1197.
19. Łukaszewska-Smyk A., Kałuzny J. Prevention of posterior capsule opacification in experimental studies. Klin Oczna 2011, 113(4-6):175-179.
20. Zaczek A., Laurell C.G., Zetterström C. Posterior capsule opacification after phacoemulsification in patients with postoperative steroidal and nonsteroidal treatment. J Cataract Refract Surg 2004, 30(2):316-320.
21. Pandey S.K., Cochener B., Apple D.J., et al. Intracapsular ring sustained 5-fluorouracil delivery system for prevention of posterior capsule opacification in rabbits; a histological study. J Cataract Refract Surg 2002, 29:139.
22. Chung H.S., Lim S.J., Kim H.B. Effect of mitomycin-C on posterior capsule opacification in rabbit eyes. J Cataract Refract Surg 2000, 26:1537.
23. Hansen T.J., Tyndall R., Soll D.B. Methotrexate-anticollagen conjugate inhibits in vitro lens cell outgrowth. Invest Ophthalmol Vis Sci 1987, 28:1206.
24. Hepsen I.F., Bayramlar H., Gultek A., et al. Caffeic acid phenethyl ester to inhibit posterior capsule opacification in rabbits. J Cataract Refract Surg 1997, 23:1572.
25. Duncan G., Wang L., Neilson G.J., Wormstone I.M. Lens cell survival after exposure to stress in the closed capsular bag. Invest Ophthalmol Vis Sci 2007, 48(6):2701-2707.
26. Sureshkumar J., Haripriya A., Muthukkaruppan V., Kaufman P.L., Tian B. Cytoskeletal drugs prevent posterior capsular opacification in human lens capsule in vitro. Graefes Arch Clin Exp Ophthalmol 2012, 250(4):507-514. [Epub ahead of print].
27. Evereklioglu C., İlhan ö. Do non-steroidal anti-inflammatory drugs delay posterior capsule opacification after phacoemulsification in children? A randomized, prospective controlled trial. Curr Eye Res 2011, 36(12):1139-1147.
28. Malecaze F., Decha A., Serre B., Penary M., Duboue M., Berg D., et al. Prevention of posterior capsule opacification by the induction of therapeutic apoptosis of residual lens cells. Gene Ther 2006, 13(5):440-448.
29. Huang W.R., Fan X.X., Tang X. SiRNA targeting EGFR effectively prevents posterior capsular opacification after cataract surgery. Mol Vis 2011, 17:2349-2355.
30. Li J., Tang X., Chen X. Comparative effects of TGFβ2/Smad2 and TGFβ2/Smad3 signaling pathways on proliferation, migration, and extracellular matrix production in a human lens cell line. Exp Eye Res 2011, 92(3):173-179.
31. Li J.H., Dong Z., Wang N.L. Experimental study on effects of matrix metalloproteinase inhibitor on posterior capsule opacification in rabbits. Zhonghua Yan Ke Za Zhi 2011, 47(4):314-319.
32. Morarescu D., West-Mays J.A., Sheardown H.D. Effect of delivery of MMP inhibitors from PDMS as a model IOL material on PCO markers. Biomaterials 2010, 31(8):2399-2407.
33. Wong T.T., Daniels J.T., Crowston J.G., Khaw P.T. MMP inhibition prevents human lens epithelial cell migration and contraction of the lens capsule. Br J Ophthalmol 2004, 88:868-872.
34. Meacock W.R., Spalton D.J., Stanford M.R. Role of cytokines in the pathogenesis of posterior capsule opacification. Br J Ophthalmol 2000, 84(3):332-336.
35. Malecaze F., Chollet P., Cavrois E., et al. Role of interleukin 6 in the inflammatory response after cataract surgery. An experimental and clinical study. Arch Ophthalmol 1991, 109:1681-1683.
36. Nishi K., Nishi O., Omoto Y. The synthesis of cytokines by human lens epithelial cells-interleukin 1 (IL-1), tumor necrosis factor (TNF) interleukin 6 (IL-6), and epidermal growth factor (EGF). Nihon Ganka Gakkai Zasshi 1992, 96(6):715-720.
37. Nishi O., Nishi K., Omoto Y. Synthesis of interleukin-1, interleukin-6, and basic fibroblast growth factor by human cataract lens epithelial cells. J Cataract Refract Surg 1996, 22:852-858.
38. Simon D., Denniston A.K., Tomlins P.J., Wallace G.R., Rauz S., Salmon M., et al. Soluble gp130, an antagonist of IL-6 trans-signaling, is elevated in uveitis aqueous humor. Invest Ophthalmol Vis Sci 2008, 49(9):3988-3991.
39. Curnow S.J., Falciani F., Durrani O.M., et al. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest Ophthalmol Vis Sci 2005, 46:4251-4259.
40. Kon C.H., Occleston N.L., Aylward G.W., Khaw P.T. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 1999, 40:705-712.
41. Shigemitsu T., Ishiguro K., Shimizu Y., Horiguchi M., Kasahara M., Arakaki S. Immunocytochemical features of lens after cataract tissue - signalling molecules (growth factors, cytokines, other signalling molecules), cytoskeleton proteins, cellular and extracellular matrix proteins. Int Ophthalmol 1999, 23(3):137-144.
42. Barnes T.C., Anderson M.E., Moots R.J. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011, 2011:721608.
43. Zenkel M., Lewczuk P., Jünemann A., Kruse F.E., Naumann G.O., Schlötzer-Schrehardt U. Proinflammatory cytokines are involved in the initiation of the abnormal matrix process in pseudoexfoliation syndrome/glaucoma. Am J Pathol 2010, 176(6):2868-2879.
44. Saika S., Okada Y., Miyamoto T., Ohnishi Y., Ooshima A., McAvoy J.W. Smad translocation and growth suppression in lens epithelial cells by endogenous TGFβeta2 during wound repair. Exp Eye Res 2001, 72:679-686.
45. Schlotzer-Schrehardt U., Zenkel M., Kuchle M., Sakai L.Y., Naumann G.O. Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res 2001, 73:765-780.
46. Ohta K., Yamagami S., Taylor A.W., Streilein J.W. IL-6 antagonizes TGFβ and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 2000, 41:2591-2599.
47. Granstein R.D., Staszewski R., Knisely T.L., et al. Aqueous humor contains transforming growth factor-β and small (<3500 daltons) inhibitor of thymocyte proliferation. J Immunol 1990, 144:3021-3026.
48. Cousins S.W., McCabe M.M., Danielpour D., Streilein J.W. Identification of transforming growth factor-beta as immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 1991, 32:2201-2211.
49. Gordon-Thomson C., de Iongh R.U., Hales A.M., Chamberlain C.G., McAvoy J.W. Differential cataractogenic potency of TGFβ1,-beta2, and -beta3 and their expression in the postnatal rat eye. Invest Ophthalmol Vis Sci 1998, 39:1399-1409.
50. Kurosaka D., Nagamoto T. Inhibitory effect of TGFβ 2 in human aqueous humor on bovine lens epithelial cell proliferation. Invest Ophthalmol Vis Sci 1994, 35:3408-3412.
51. Gotoh N., Perdue N.R., Matsushima H., Sage E.H., Yan Q., Clark J.I. An in vitro model of posterior capsular opacity: SPARC and TGFβ2 minimize epithelial-to-mesenchymal transition in lens epithelium. Invest Ophthalmol Vis Sci 2007, 48(10):4679-4687.
52. Yao K., Ye P.P., Tan J., Tang X.J. Shen Tu XC. Involvement of PI3K/Akt pathway in TGFβ2-mediated epithelial mesenchymal transition in human lens epithelial cells. Ophthalmic Res 2008, 40(2):69-76.
53. Oloumi A., McPhee T., Dedhar S. Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta 2004, 1691:1-15.
54. Peinado H., Quintanilla M., Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003, 278:21113-21123.
55. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012, 1825(1):29-36.
56. Tamiya S., Wormstone I.M., Marcantonio J.M., Gavrilovic J., Duncan G. Induction of matrix metalloproteinases 2 and 9 following stress to the lens. Exp Eye Res 2000, 71(6):591-597.
57. Tholozan F.M., Gribbon C., Li Z., Goldberg M.W., Prescott A.R., McKie N., et al. FGF-2 release from the lens capsule by MMP-2 maintains lens epithelial cell viability. Mol Biol Cell 2007, 18:4222-4231.
58. Sivak J.M., Fini M.E. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res 2002, 21:1-14.
59. Hodgkinson L.M., Duncan G., Wang L., Pennington C.J., Edwards D.R., Wormstone I.M. MMP and TIMP expression in quiescent, dividing, and differentiating human lens cells. Invest Ophthalmol Vis Sci 2007, 48(9):4192-4199.
60. Smine A., Plantner J.J. Membrane type I metalloproteinase in human ocular tissues. Curr Eye Res 1997, 16:925-929.
61. Vaughan-Thomas A., Gilbert S.J., Duance V.C. Elevated levels of proteolytic enzymes in the aging human vitreous. Invest Ophthalmol Vis Sci 2000, 41:3299-3304.
62. Di Girolamo N., Verma M.J., McCluskey P.J., Lloyd A., Wakefield D. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res 1996, 15(10):1060-1068.
63. Kosano H., Okano T., Katsura Y., Noritake M., Kado S., Matsuoka T., et al. ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci 1999, 64:2307-2315.
64. Alapure B.V., Praveen M.R., Gajjar D., Vasavada A.R., Rajkumar S., Johar K. Matrix metalloproteinase-9 activity in human lens epithelial cells of cortical, posterior subcapsular, and nuclear cataracts. J Cataract Refract Surg 2008, 34(12):2063-2067.
65. Richiert D.M., Ireland M.E. Matrix metalloproteinase secretion is stimulated by TGFβ in cultured lens epithelial cells. Curr Eye Res 1999, 19:269-275.
66. Dwivedi D.J., Pino G., Banh A., Nathu Z., Howchin D., Margetts P., et al. Matrix metalloproteinase inhibitors suppress transforming growth factor-beta-induced subcapsular cataract formation. Am J Pathol 2006, 168(1):69-79.
67. Seomun Y., Kim J., Lee E.H., Joo C.K. Overexpression of matrix metalloproteinase-2 mediates phenotypic transformation of lens epithelial cells. Biochem J 2001, 358(Pt 1):41-48.
68. Butler G.S., Butler M.J., Atkinson S.J., Will H., Tamura T., van Westrum S.S., et al. The TIMP2 membrane type I metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998, 273:871-880.
69. Alapure B.V., Praveen M.R., Gajjar D.U., Vasavada A.R., Parmar T.J., Arora A.I. Matrix metalloproteinase-2 and -9 activities in the human lens epithelial cells and serum of steroid induced posterior subcapsular cataracts. Mol Vis 2012, 18:64-73.
70. Hosler M.R., Wang-Su S.T., Wagner B.J. Role of the proteasome in TGFβ signaling in lens epithelial cells. Invest Ophthalmol Vis Sci 2006, 47:2045-2052.
71. Awasthi N., Wang-Su S.T., Wagner B.J. Downregulation of MMP-2 and -9 by proteasome inhibition: a possible mechanism to decrease LEC migration and prevent posterior capsular opacification. Invest Ophthalmol Vis Sci 2008, 49(5):1998-2003.
72. Aida Y., Honda K., Tanigawa S., Nakayama G., Matsumura H., Suzuki N., et al. IL-6 and soluble IL-6 receptor stimulate the production of MMPs and their inhibitors via JAK-STAT and ERK-MAPK signalling in human chondrocytes. Cell Biol Int 2012, 36(4):367-376. [Epub ahead of print].
73. Kobara M., Noda K., Kitamura M., Okamoto A., Shiraishi T., Toba H., et al. Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice. Cardiovasc Res 2010, 87:424-430.
74. Planck S.R., Dang T.T., Graves D., Tara D., Ansel J.C., Rosenbaum J.T. Retinal pigment epithelial cells secrete interleukin-6 in response to interleukin-1. Invest Ophthalmol Vis Sci 1992, 33:78-82.
75. May L.T., Torna C., Cozzolino F. Interleukin-6 gene expression in human endothelial cells: RNA start sites, multiple IL-6 proteins and inhibition of proliferation. Biochem Biophys Res Commun 1989, 159:991-998.
76. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008, 14(3):109-119.
77. Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989, 58:573-581.
78. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998, 16:249-284.
79. Huang C., Yang G., Jiang T., Zhu G., Li H., Qiu Z. The effects and mechanisms of blockage of STAT3 signaling pathway on IL-6 inducing EMT in human pancreatic cancer cells in vitro. Neoplasma 2011, 58(5):396-405.
80. Legendre F., Bogdanowicz P., Boumediene K., Pujol J.P. Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular. J Rheumatol 2005, 32:1307-1316.
81. Huang C., Yang G., Jiang T., Huang K., Cao J., Qiu Z. Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res 2010, 29(5):51.
82. Hurst S.M., Wilkinson T.S., McLoughlin R.M., Jones S., Horiuchi S., Yamamoto N., et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001, 14:705-714.
83. Jones S.A., Richards P.J., Scheller J., Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005, 25(5):241-253.
84. Petrinović-Doresić J., Mazuran R., Henc-Petrinović L., Kuzmanović B., Jovicić A. Interleukin 6 and its soluble receptor are elevated in aqueous humor of patients with uveitis. Ocul Immunol Inflamm 1999, 7(2):75-84.
85. Curnow S.J., Scheel-Toellner D., Jenkinson W., Raza K., Durrani O.M., Faint J.M., et al. Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J Immunol 2004, 173(8):5290-5297.
86. Canataroglu H., Varinli I., Ozcan A.A., Canataroglu A., Doran F., Varinli S. Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm 2005, 13(5):375-381.
87. Atreya R., Mudter J., Finotto S., et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000, 6:583-588.
88. Nowell M.A., Richards P.J., Horiuchi S., et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003, 171:3202-3209.
89. Wolter J.R. Cytopathology of intraocular lens implantation. Ophthalmology 1985, 92(1):135-142.
90. Lois N., Dawson R., McKinnon A.D., Forrester J.V. A new model of posterior capsule opacification in rodents. Invest Ophthalmol Vis Sci 2003, 44(8):3450-3457.
91. Nasisse M.P., Dykstra M.J., Cobo L.M. Lens capsule opacification in aphakic and pseudophakic eyes. Graefes Arch Clin Exp Ophthalmol 1995, 233(2):63-70.
92. Apple D.J., Solomon K.D., Tetz M.R., et al. Posterior capsule opacification. Surv Ophthalmol 1992, 37:73-116.
93. Saika S. Relationship between posterior capsule opacification and intraocular lens biocompatibility. Prog Retin Eye Res 2004, 23(3):283-305.
94. Ram J., Gupta A., Kumar S., Kaushik S., Gupta N., Severia S. Phacoemulsification with intraocular lens implantation in patients with uveitis. J Cataract Refract Surg 2010, 36(8):1283-1288.
95. Rahman I., Jones N.P. Long-term results of cataract extraction with intraocular lens implantation in patients with uveitis. Eye (Lond) 2005, 19(2):191-197.
96. Sakkas L.I., Xu B., Artlett C.M., Lu S., Jimenez S.A., Platsoucas C.D. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002, 168:3649-3659.
97. Bresser P., Jansen H.M., Weller F.R., Lutter R., Out T.A. T-cell activation in the lungs of patients with systemic sclerosis and its relation with pulmonary fibrosis. Chest 2001, 120(Suppl):66-68.
98. Sugita S., Horie S., Yamada Y., Kawazoe Y., Takase H., Mochizuki M. Suppression of interleukin-17-producing T-helper 17 cells by retinal pigment epithelial cells. Jpn J Ophthalmol 2011, 55(5):565-575. Epub 2011 Jul 13.
99. Yoshimura T., Sonoda K.H., Ohguro N., Ohsugi Y., Ishibashi T., Cua D.J., et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 2009, 48(4):347-354. Epub 2009 Jan 22.
100. Jiang S., Liu X., Luo L., Qu B., Huang X., Lin Y., et al. Serum levels of Th17-related cytokines in Behçet disease patients after cataract surgery. Mol Vis 2011, 17:1425-1430. Epub 2011 May 31.
101. Süllü Y., Oge I., Erkan D. The results of cataract extraction and intraocular lens implantation in patients with Behçet's disease. Acta Ophthalmol Scand 2000, 78(6):680-683.
102. Luttikhuizen D.T., Harmsen M.C., Van Luyn M.J. Cellular and molecular dynamics in the foreign body reaction. Tissue Eng 2006, 12(7):1955-1970.
103. Jiang Q., Zhou C., Bi Z., Wan Y. EGF-induced cell migration is mediated by ERK and PI3K/AKT pathways in cultured human lens epithelial cells. J Ocul Pharmacol Ther 2006, 22(2):93-102.
104. Lo H.W., Hsu S.C., Xia W., Cao X., Shih J.Y., Wei Y., et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 2007, 67(19):9066-9076.
105. Gallucci R.M., Lee E.G., Tomasek J.J. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J Invest Dermatol 2006, 126(3):561-568.
106. Poncet N., Guillaume J., Mouchiroud G. Epidermal growth factor receptor transactivation is implicated in IL-6-induced proliferation and ERK1/2 activation in non-transformed prostate epithelial cells. Cell Signal 2011, 23(3):572-578.
107. Walker J.L., Wolff I.M., Jhang L., Menko A.S. Activation of SRC kinases signals induction of posterior capsule opacification. Invest Ophthalmol Vis Sci 2007, 48:2214-2223.
108. Bain J., McLauchlan H., Elliott M., Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003, 371(Pt 1):199-204.
109. Perng D.W., Chang K.T., Su K.C., Wu Y.C., Chen C.S., Hsu W.H., et al. Matrix metalloprotease-9 induces transforming growth factor-β(1) production in airway epithelium via activation of epidermal growth factor receptors. Life Sci 2011, 89(5-6):204-212.
110. Luckett-Chastain L.R., Gallucci R.M. Interleukin (IL)-6 modulates transforming growth factor-beta expression in skin and dermal fibroblasts from IL-6-deficient mice. Br J Dermatol 2009, 161(2):237-248.
111. Smith E.A. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol 1992, 4:869-877.
112. Christner P.J., Jimenez S.A. Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches. Curr Opin Rheumatol 2004, 16:746-752.
113. Pajulo O.T., Pulkki K.J., Alanen M.S., et al. Correlation between interleukin-6 and matrix metalloproteinase-9 in early wound healing in children. Wound Repair Regen 1999, 7:453-457.
114. Kossakowska A.E., Edwards D.R., Prusinkiewicz C., et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999, 94:2080-2089.
115. Luckett L.R., Gallucci R.M. Interleukin-6 (IL-6) modulates migration and matrix metalloproteinase function in dermal fibroblasts from IL-6KO mice. Br J Dermatol 2007, 156:1163-1171.
116. Symeonidis C., Papakonstantinou E., Androudi S., Rotsos T., Diza E., Brazitikos P., et al. Interleukin-6 and the matrix metalloproteinase response in the vitreous during proliferative vitreoretinopathy. Cytokine 2011, 54(2):212-217.